We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.
- Authors
Meckley, Lisa M; Gudgeon, James M; Anderson, Jeffrey L; Williams, Marc S; Veenstra, David L
- Abstract
In 2007, the US FDA added information about pharmacogenomics to the warfarin label based on the influence of the CYP2C9 and VKORC1 genes on anticoagulation-related outcomes. Payers will be facing increasing demand for coverage decisions regarding this technology, but the potential clinical and economic impacts of testing are not clear.
- Publication
PharmacoEconomics, 2010, Vol 28, Issue 1, p61
- ISSN
1179-2027
- Publication type
Journal Article
- DOI
10.2165/11318240-000000000-00000